Bruker Corp Stock Price, News & Analysis

Bruker recently showcased its innovative Ascend Evo 1.0 GHz NMR magnet at the Experimental Nuclear Magnetic Resonance Conference, designed to operate at 4.2 Kelvin for structural biology in standard labs. This new technology boasts a significant reduction in liquid helium consumption by threefold, enhancing accessibility for researchers. Additionally, Bruker introduced the Heliosmart Recovery system which enables the collection of helium gas boil-off, achieving recovery rates of 80%-85%. The company continues to offer services like LabScape Remote Monitoring for effective management of NMR magnets.

Bruker Corporation (Nasdaq: BRKR) recently introduced advancements in its MALDI Biotyper® platform and launched new multiplex PCR assays at the 32nd European Congress of Clinical Microbiology & Infectious Diseases. Key offerings include the FluoroType® Mycobacteria PCR assay, which differentiates 32 mycobacteria species, and the FluoroType® STI PCR assay, which detects seven major STI pathogens. These innovations enhance Bruker's portfolio in infectious disease diagnostics, leveraging its LiquidArray® technology for improved accuracy and speed in clinical settings.

Bruker Corporation (NASDAQ: BRKR) will report its first quarter 2022 financial results on May 4, 2022, before market opening. A conference call and webcast will take place at 8:30 a.m. Eastern Time to discuss these results and current business trends. Investors can access the webcast through Bruker's investor relations website or via telephone. A replay will be available starting one hour after the call until June 4, 2022. Bruker continues to support scientific innovation and diagnostics in various research fields.

Bruker Corporation (Nasdaq: BRKR) has unveiled innovative technologies at the AACR Annual Meeting 2022, focusing on spatial multiomics and single-cell proteomics for cancer research. Key launches include the MALDI HiPLEX-IHC tissue imaging solution, which integrates protein mapping with small molecule imaging, and the CellScape™ platform for high-precision spatial proteomics. The timsTOF fleX platform can identify over 13,000 proteins, advancing the capabilities in cancer profiling. These advancements position Bruker to enhance cancer research methodologies significantly.

Bruker Corporation (BRKR) has successfully acquired IonSense Inc., a leader in ambient DART ionization technology. This acquisition aims to enhance the development of DART ionization sources and expand applications in food analysis and forensics. IonSense will leverage Bruker's financial investments to accelerate their product development and reach a broader market. The DART technology uniquely analyzes solids, liquids, and gases without prior chromatography, offering faster sample identification. This merger positions Bruker to further tap into the $4B mass spectrometry marketplace.

Bruker Corporation (NASDAQ: BRKR) has announced the acquisition of Optimal Industrial Automation and Technologies, enhancing its role in pharmaceutical process analytical technology (PAT) and manufacturing automation. The acquisition is expected to complement Bruker's existing offerings in high-value NMR and mass spectrometry, positioning them as a key software provider for the biopharma sector. While financial specifics were not disclosed, Optimal's 2022 revenue is projected at $10 million, with anticipated positive impacts on Bruker's revenue and operating margins.

Bruker Corporation (Nasdaq: BRKR) has unveiled enhanced capabilities for proteomic and epiproteomic analysis using its innovative TIMScore™ algorithm integrated into the PaSER 2022 system. This new technology allows for the identification of over 8000 protein groups in just 35 minutes while improving phosphopeptide identification by more than 25%. With access to ultra-deep libraries of over 13,000 protein groups, the TIMScore™ algorithm enhances peptide confidence and coverage, supporting high-throughput translational proteomics.

Bruker Corporation (NASDAQ: BRKR) has announced the appointment of Philip Ma, Ph.D., to its Board of Directors, effective April 1, 2022. Dr. Ma is the CEO and founder of PrognomiQ and has significant experience in life sciences, particularly in multiomics and cancer diagnostics. His previous roles include leadership positions at Biogen and McKinsey & Company. The company aims to leverage his expertise to advance its Project Accelerate 2.0 initiatives, which focus on enhancing life science and clinical research tools.

Bruker Corporation (NASDAQ: BRKR) announced enhanced capabilities for its Fourier 80 benchtop FT-NMR spectrometer, now featuring an Adjustable Temperature option for samples between 25°C to 60°C. This upgrade expands applications in pharmaceutical and food analysis, improving synthesis and process control. The introduction of the RxnLab™ solution offers temperature-controlled monitoring of reactions, while the Olive Oil-Profiling™ 1.0 solution supports olive oil authenticity analysis. The enhancements aim to elevate research capabilities in various analytical laboratories.